Antiarrhythmic efficacy of combined IKs and β-adrenergic receptor blockade

Journal of Pharmacology and Experimental Therapeutics

Volumn 302, Issue 1, 2002, Pages 283-289

  Lynch Jr , Joseph J ^a,b   Salata, Joseph J ^a   Wallace, Audrey A ^a   Stump, Gary L ^a   Gilberto, David B ^a   Jahansouz, Hossain ^a   Liverton, Nigel J ^b   Selnick, Harold G ^b   Claremon, David A ^b  

^a Department of Pharmacology ^*  (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,4 TRIFLUOROMETHYLPHENYL) N [2 OXO 5 PHENYL 1 (2,2,2 TRIFLUOROETHYL) 2,3 DIHYDRO 1H BENZO[E][1,4]DIAZEPIN 3 YL]ACETAMIDE; 3 (2,4 DICHLOROPHENYL) N (1 METHYL 2 OXO 5 PHENYL 2,3 DIHYDRO 1H BENZO[E][1,4]DIAZEPIN 3 YL)ACRYLAMIDE; ACRYLAMIDE DERIVATIVE; ANTIARRHYTHMIC AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; I KAPPA B; I KAPPA S; L 735821; L 768673; TIMOLOL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; DISEASE MODEL; DOG; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SELECTIVITY; FEMALE; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE REFRACTORY PERIOD; HEART STIMULATION; HEART VENTRICLE ARRHYTHMIA; ISCHEMIA; LETHALITY; MALE; NONHUMAN; PRIORITY JOURNAL; QT INTERVAL; RECEPTOR BLOCKING;

ACETAMIDES; ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; BENZODIAZEPINONES; DOGS; ELECTRIC STIMULATION; ELECTROPHYSIOLOGY; FEMALE; HEART; HEART RATE; HEART VENTRICLES; ISOPROTERENOL; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; POTASSIUM CHANNEL BLOCKERS; TIMOLOL;

EID: 0036085523     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.302.1.283     Document Type: Article

References (40)

1. Ks-blocking agent chromanol 293b on individual muscle layers of the intact canine heart
2. Ks-blocking agent chromanol 293b in the postinfarction canine heart. Preserved positive use-dependence and preferential prolongation of refractoriness in the infarct zone
3. + current, on repolarization in human and guinea pig ventricular myocytes
4. Ks does not induce early after-depolarization activity but promotes β-adrenergic agonist-induced delayed after-depolarization activity
5. Ks in guinea pig cardiac myocytes and guinea pig IsK channels by the chromanol 293b
6. + currents in rabbit heart Purkinje cells
7. Comparative effects of antiarrhythmic drugs on the ventricular fibrillation threshold
8. Effects of timolol and propranolol on inducible sustained ventricular tachyarrhythmias in dogs with subacute myocardial infarction
9. Ks channel blockers: Potential antiarrhythmic agents
10. Ks channels by HMR 1556
11. Slow delayed rectifier current and repolarization in canine cardiac Purkinje cells
12. Class III antiarrhythmic agents have a lot of potential but a long way to go
13. Ks) fails to lengthen rabbit ventricular muscle QTc and action potential duration
14. + current in human ventricular myocytes
15. Ks contributes to the longer action potential of the M cell
16. Ks, in canine models of malignant ischemic ventricular arrhythmia
17. Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias
18. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome
19. Frequency-dependent effects of antiarrhythmic drugs on action potential duration and refractoriness of canine cardiac Purkinje fibers
20. Genetic and molecular basis of cardiac arrhythmias: Impact on clinical management. Parts I and II
21. Prevention of sudden death by beta-blockade
22. Ks
23. Ks in guinea pig ventricular myocytes
24. + current: Differential sensitivity to block by Class III antiarrhythmic agents
25. Isoproterenol antagonizes prolongation of refractory period by the Class III antiarrhythmic agent E-4031 in guinea pig myocytes
26. Differential effect of β-adrenergic stimulation on the frequency-dependent electrophysiologic actions of the new Class III antiarrhythmics dofetilide, ambasilide and chromanol 293b
27. Do animal models have clinical relevance?
28. Genotype-phenotype correlation in the long-QT syndrome: Gene-specific triggers for life-threatening arrhythmias
29. Ks by (R)-2-(2,4-trifluoromethyl)-N-[2-oxo-5-phenyl-l-(2,2,2-trifluoroethyl) -2,3-dihydro-lH-benzo[e][1,4] diazepin-3-yl]-acetamide (L-768673)
30. Differential effects of beta-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome
31. Class III action of beta-blocking agents
32. Dofetilide in patients with congestive heart failure and left ventricular dysfunction
33. + channel blockade in the prevention of ventricular fibrillation in dogs with acute ischemia and enhanced sympathetic activity
34. Ks in dog ventricular muscle and Purkinje fiber repolarization
35. Effectiveness of beta-blockers in the LQT1 genotype of long QT syndrome
36. The slow component of the delayed rectifier potassium current in undiseased human ventricular myocytes
37. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction
38. Rapid and slow components of delayed rectifier current in human atrial myocytes
39. Ventricular arrhythmias: Mechanisms and actions of antiarrhythmic drugs
40. Left ventricular hypertrophy decreases slowly but not rapidly activating delayed rectifier potassium currents of epicardial and endocardial myocytes in rabbits